Recent Posts
- Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
- Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
- Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
- Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
- Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
Recent Comments
No comments to show.